Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
UBS
Harvard Business School
Chubb
Novartis
Teva
Cantor Fitzgerald
Argus Health
Deloitte
Colorcon

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,745,460

« Back to Dashboard

Which drugs does patent 7,745,460 protect, and when does it expire?

Patent 7,745,460 protects XIIDRA and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.
Summary for Patent: 7,745,460
Title:Modulators of cellular adhesion
Abstract: The present invention provides compounds having formula (I): ##STR00001## and pharmaceutically acceptable derivatives thereof, wherein R.sub.1-R.sub.4, n, p, A, B, D, E, L and AR.sup.1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
Inventor(s): Shen; Wang (San Mateo, CA), Barr; Kenneth (San Francisco, CA), Oslob; Johan D. (Sunnyvale, CA), Zhong; Min (Foster City, CA)
Assignee: SARcode Corporation (San Francisco, CA)
Application Number:11/978,388
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,745,460

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,745,460

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,314,938 Modulators of cellular adhesion ➤ Try a Free Trial
7,989,626 Modulators of cellular adhesion ➤ Try a Free Trial
8,071,617 Modulators of cellular adhesion ➤ Try a Free Trial
9,248,126 Modulators of cellular adhesion ➤ Try a Free Trial
9,216,174 Modulators of cellular adhesion ➤ Try a Free Trial
7,790,743 Modulators of cellular adhesion ➤ Try a Free Trial
7,928,122 Modulators of cellular adhesion ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,745,460

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1682537 ➤ Try a Free Trial
Portugal 1682537 ➤ Try a Free Trial
Japan 2016147908 ➤ Try a Free Trial
Japan 2014196353 ➤ Try a Free Trial
Japan 5840582 ➤ Try a Free Trial
Japan 2013010778 ➤ Try a Free Trial
Japan 5105578 ➤ Try a Free Trial
Japan 2007513081 ➤ Try a Free Trial
Hong Kong 1095815 ➤ Try a Free Trial
Spain 2383525 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
QuintilesIMS
Argus Health
Chubb
Chinese Patent Office
Farmers Insurance
Express Scripts
Julphar
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot